Skip to content
ADAPTILENS ANNOUNCES $17.5M SERIES A FINANCING
  • Home
  • Our Technology
  • Team
  • News
  • Contact
  • Home
  • Our Technology
  • Team
  • News
  • Contact

News

  • All News
  • In the Media
  • Announcements
  • Publications
  • All News
  • In the Media
  • Announcements
  • Publications

Adaptilens Announces $17.5M in Series A Financing​

April 29, 2024

We are thrilled to announce that Adaptilens has secured $17.5 million in Series A financing, led by Xontogeny and Perceptive Xontogeny Venture Fund, with participation

Read More »

Adaptilens Featured in C&EN: Celebrating Founder-Led Biotech Innovation

November 13, 2024
Read More »

Adaptilens Announces $17.5M in Series A Financing​

April 29, 2024
Read More »

Dr. Clamen featured in the When Science Speaks podcast

October 22, 2022
Read More »

Dr. Clamen featured in the Amazing Execs episode 102 “Developing a Breakthrough New Ophthalmic Medical Device”

July 26, 2022
Read More »

Adaptilens won a $75,000 Grand Prize award at the Harvard Innovation Lab’s President’s Innovation Challenge

May 3, 2022
Read More »

Adaptilens chosen to participate in Harvard’s highly selective Launch Lab X GEO accelerator

October 25, 2021
Read More »

Dr. Clamen receives the 2021 Massachusetts Next Generation award

June 14, 2021
Read More »

Polymeric Materials for Eye Surface and Intraocular Applications

January 6, 2021
Read More »

Announcing $1.6 million in seed funding led by Pillar VC additional participation from Accanto Partners

November 12, 2020
Read More »

Adaptilens selected as a finalist for the 2020 MassChallenge Boston program

June 3, 2020
Read More »
Updates
Follow Adaptilens on Linkedin
Adaptilens is made possible with help from​
notice: The Adaptilens is in the development phase and is not yet approved for investigational or commercial use.

Follow our progress on

Linkedin